Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Vaccines have modest impact on influenza in healthy adults
Vault Navigation
Vaccines have modest impact on influenza in healthy adults
How effective are vaccines against influenza in healthy adults?
Healthy adults who received inactivated parenteral influenza vaccine rather than no vaccine probably had a 1% lower risk of experiencing influenza over a single influenza season (2.3% versus 1%, moderate-certainty evidence) and probably had a 3.4% lower risk of experiencing influenza-like illness (ILI; 21.5% versus 18.1%, moderate-certainty evidence). The numbers needed to vaccinate (NNVs) for influenza and ILI were 71 and 29, respectively, reflecting high rates of ILI in the control groups for many of the trials. The NNV of 29 conceals variation in the absolute reduction in ILI for low and high-risk groups, and the degree of benefit may vary at least in part due to inconsistent symptom classification.
Extrapolating these effects to settings other than those of the studies is challenging due to uncertain methods for confirming influenza and variation in the absolute reductions in ILI following vaccination. The effects of inactivated vaccines on working days lost or serious complications of influenza were uncertain.
Viral respiratory disease imposes a heavy burden on society. The majority of viral respiratory disease (ILI) is caused by many different agents that are not clinically distinguishable from one another. A variable proportion of ILI (7–15% on average) is caused by influenza viruses and is known as influenza.
Demicheli V et al. Vaccines for preventing influenza in healthy adults. Cochrane Reviews, 2018, Issue 2. Art. No.: CD001269.DOI: 10.1002/14651858. CD001269.pub6. This review contains 52 studies involving over 80,000 participants.